All In Biotech

Drug Trial Radar · NCT00145925

Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes

ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation

Last checked: Nov 19, 2026Latest source record: Apr 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 11,140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

11,140

Actual

Start

Jun 2001

Primary completion

Mar 2008

Study completion Mar 2008

Sponsor

Lead sponsor
The George InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Institut de Recherches Internationales Servier; University of Sydney; National Health and Medical Research Council, Australia
First posted
Sep 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Double
Primary purpose
Prevention
Who can join
All sexes, from 55 years, up to 110 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide information on the risks and benefits of routine blood pressure lowering (regardless of blood pressure level), and intensive lowering of blood glucose levels, in patients with Type 2 diabetes at high risk of cardiovascular events. The major outcomes of the study will be cardiovascular events (heart attack, stroke or dying as a result of cardiovascular disease), as well as new or worsening diabetic eye and kidney disease.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Perindopril-indapamideDrug

  • Gliclazide MR-based glucose loweringDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of non-fatal stroke, non-fatal myocardial infarction or death from any cardiovascular causeTime frame: July 2001 - December 2007
  2. Composite of new or substantially worsening nephropathy or microvascular eye disease.Time frame: July 2001 - December 2007

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • The University of Melbourne

    Melbourne, Victoria, Australia

  • University of Montreal

    Montreal, Quebec, Canada

  • Cardiovascular Institute & Fu Wai Hospital

    Beijing, Beijing Municipality, China

  • The Julius Center for Health Sciences and Primary Care

    Utrecht, Utrecht, Netherlands

  • Imperial College School of Medicine

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.